预约演示
Silence breaks down phase 1 data on blood disorder prospect, sharing glimpse at pitch for competitive niche
2024-06-27
临床3期临床结果上市批准临床1期
Incyte’s Jakafi and PharmaEssentia’s Besremi are already approved in polycythemia vera.
Incytee TJakafiuticsPharmaEssentia abBesremi phase 1 polycythemia verpolycythemia verarial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda.
Silence Therapeuticsregular blood draws, a procedure polycythemia vera (PV) to reduce the number of blood cells and decrease blood volume. At baseline, all subjects in SiIncytes triTakeda undergone at least three phlebotomies in the past six months or five phlebotomies in the past year. In total, the participants underwent 59 blood draws in the six months before starting the study.
The data set features 16 patients split across three doses of divesiran. Silence enrolled participants with levels of hematocrit above and below the threshold it has identified as increasing the risk of thrombotic and cardiovascular events.
None of the participants with well-controlled hematocrit at badivesiranderwent a phlebotomy during the follow-up period, which ranged from four to 34 weeks in the data set. Two patients on the middle dose had one blood draw each. The patients who needed phlebotomies had the highest hematocrit at baseline.
Silence also showed how levels of hematocrit changed over time in the first two dose cohorts. Levels trended down in the cohorts and fell below the risk threshold identified by Silence. However, the cohorts are small, featuring 12 patients in total, and the error bars are wide. Silence saw a bigger change at the higher of the two doses, leading it to say the data suggest a potential dose response.
No patients had drug-related serious adverse events or withdrew because of divesiran side effects. The results position Silence to continue toward the conclusion of the study, enrollment in which is scheduled to wrap up this month, but leave questions about the competitiveness of divesiran unanswered.
Incyte’s Jakafi and PharmaEssentia’s Besremi are already approved in the indication, although both leave room for improvement. Takeda is leading the charge to deliver a better PV drug. Having paid Protagonist Therapeutics $300 million upfront early this year, the Japanese drugmaker has rights to the phase 3 PV prospect rusfertide.
IncyteoniJakafiolecuPharmaEssentiatabBesremiide mimetic of the master iron regulatory hormone hepcidin. Divesiran is designed to inhibit expression of a target involved in hepcidin expression. The Protagonist Therapeuticsdifferent ways of achieving the same goal, namely raising hepcidin to lower the production of red blrusfertide
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。